NCT00908310View on ClinicalTrials.gov

Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)

PHASE4CompletedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

June 30, 2013

Study Completion Date

September 30, 2013

Conditions
Chronic Kidney DiseaseRenal Insufficiency
Interventions
DRUG

Omniscan

OMNISCAN will be administered intravenously at the medical discretion of the prescribing physician.

Trial Locations (1)

08540

GE Healthcare, Princeton

Sponsors

Lead Sponsor

GE Healthcare
All Listed Sponsors
collaborator

i3 Statprobe

INDUSTRY

lead

GE Healthcare

INDUSTRY